Use of high-plex data provides novel insights into the temporal artery processes of giant cell arteritis
Frontiers in Immunology · 2023
DOI: 10.3389/fimmu.2023.1237986 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, 2023. Verfasst von Simon Parreau und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Mayo Clinic, Rochester, MN, United States. Hauptthemen laut MEDLINE: Giant Cell Arteritis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIAMS NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Objective
To identify the key coding genes underlying the biomarkers and pathways associated with giant cell arteritis (GCA), we performed an in situ spatial profiling of molecules involved in the temporal arteries of GCA patients and controls. Furthermore, we performed pharmacogenomic network analysis to identify potential treatment targets.
Methods
Using human formalin-fixed paraffin-embedded temporal artery biopsy samples (GCA, n = 9; controls, n = 7), we performed a whole transcriptome analysis using the NanoString GeoMx Digital Spatial Profiler. In total, 59 regions of interest were selected in the intima, media, adventitia, and perivascular adipose tissue (PVAT). Differentially expressed genes (DEGs) (fold-change > 2 or < −2, p-adjusted < 0.01) were compared across each layer to build a spatial and pharmacogenomic network and to explore the pathophysiological mechanisms of GCA.
Results
Most of the transcriptome (12,076 genes) was upregulated in GCA arteries, compared to control arteries. Among the screened genes, 282, 227, 40, and 5 DEGs were identified in the intima, media, adventitia, and PVAT, respectively. Genes involved in the immune process and vascular remodeling were upregulated within GCA temporal arteries but differed across the arterial layers. The immune-related functions and vascular remodeling were limited to the intima and media.
Conclusion
This study is the first to perform an in situ spatial profiling characterization of the molecules involved in GCA. The pharmacogenomic network analysis identified potential target genes for approved and novel immunotherapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Mayo Clinic, Rochester, MN, United States.
- Division of Internal Medicine, Dupuytren University Hospital, Limoges, France.
- INSERM U1308, Faculty of Medicine, University of Limoges, Limoges, France.
- Stem Cell Genomics Core, Stem Cell Program, University of California, San Diego, La Jolla, CA, United States.
- Next Generation Sequencing Core, Salk Institute for Biological Studies, La Jolla, CA, United States.
- Division of Internal Medicine, Nîmes University Hospital, University of Montpellier, Nîmes, France.
Förderung
- NIAID NIH HHS
- NIAMS NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Parreau, S., Molina, E., Dumonteil, S., Goulabchand, R., Naves, T., Bois, M. C., Akil, H., Terro, F., Fauchais, A. L., Liozon, E., Jauberteau, M. O., Weyand, C. M., & Ly, K. H. (2023). Use of high-plex data provides novel insights into the temporal artery processes of giant cell arteritis. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1237986
Vancouver
Parreau S, Molina E, Dumonteil S, Goulabchand R, Naves T, Bois MC, et al. Use of high-plex data provides novel insights into the temporal artery processes of giant cell arteritis. Frontiers in Immunology. 2023. doi:10.3389/fimmu.2023.1237986
BibTeX
@article{Parreau2023,
author = {Parreau, Simon and Molina, Elsa and Dumonteil, Stéphanie and Goulabchand, Radjiv and Naves, Thomas and Bois, Melanie C and Akil, Hussein and Terro, Faraj and Fauchais, Anne-Laure and Liozon, Eric and Jauberteau, Marie-Odile and Weyand, Cornelia M and Ly, Kim-Heang},
title = {Use of high-plex data provides novel insights into the temporal artery processes of giant cell arteritis},
journal = {Frontiers in Immunology},
year = {2023},
doi = {10.3389/fimmu.2023.1237986}
}
EUVIMED